Irhythm Technologies Inc Stock Price, News & Analysis

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection and prediction solutions, has announced its participation in three upcoming investor conferences in September 2025.

The company will present at the Wells Fargo Healthcare Conference on September 3 at 12:45 PM ET, the Morgan Stanley Global Healthcare Conference on September 9 at 2:35 PM ET, and the Baird Global Healthcare Conference on September 10 at 12:50 PM ET. Webcasts will be available on the company's investor relations website.

iRhythm Technologies (NASDAQ:IRTC) announced groundbreaking results from the AVALON study, the largest real-world evaluation of ambulatory cardiac monitoring involving 428,707 commercially insured patients. The study, published in the American Journal of Managed Care, demonstrates the clinical superiority of iRhythm's Zio long-term continuous monitoring (LTCM) service.

The Zio LTCM service showed remarkable advantages over competitors, achieving the highest diagnostic yield (26.5%) compared to other monitoring services, fastest time to diagnosis (9 days), and lowest total healthcare costs ($10,476 per patient-year). The study revealed that Zio LTCM was up to 2.04 times more likely to diagnose arrhythmias compared to Holter monitors and demonstrated the lowest retest rate of 3.1% within 180 days.

iRhythm Technologies (NASDAQ:IRTC) has announced a strategic partnership with Lucem Health to develop an AI-powered solution for early arrhythmia detection. The collaboration's first commercial offering will use predictive AI to analyze clinical and EHR data to identify arrhythmia risk in patients with Type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease.

The solution integrates with iRhythm's Zio® ECG monitors and service, providing up to 14 days of continuous heart monitoring. Early pilot testing has shown promising results in targeting high-risk populations. The partnership aims to address an estimated 27 million undiagnosed patients in the U.S., targeting healthcare organizations focused on population health management and value-based care strategies.

Recent research presented at various medical conferences demonstrates that arrhythmia patients with comorbid conditions experience up to 2x higher hospitalization rates and 35-50% higher emergency care costs, with average annual healthcare expenses of $46,000 compared to $30,000 for those without arrhythmias.

iRhythm Technologies (NASDAQ: IRTC) reported strong Q2 2025 financial results, with revenue reaching $186.7 million, up 26.1% year-over-year. The company achieved a gross margin of 71.2%, representing a 130-basis point improvement from Q2 2024.

Key operational highlights include record quarterly revenue driven by core long-term monitoring business growth, Zio AT demand, and progress in value-based care. The company formed a strategic partnership with Lucem Health for AI-driven arrhythmia detection and presented significant findings at ADA 2025 regarding cardiac arrhythmias in cardiometabolic populations.

Despite revenue growth, IRTC reported a net loss of $14.2 million ($0.44 per share), improved from a $20.1 million loss year-over-year. The company raised its 2025 guidance, projecting full-year revenue of $720-730 million with adjusted EBITDA margin of 8.0-8.5%.

[ "Revenue grew 26.1% year-over-year to $186.7 million", "Gross margin improved 130 basis points to 71.2%", "Strong cash position with $545.5 million in unrestricted cash and equivalents", "Net loss improved from $20.1M to $14.2M year-over-year", "Increased full-year 2025 revenue and adjusted EBITDA guidance", "Strategic AI partnership with Lucem Health for enhanced arrhythmia detection" ]

iRhythm Technologies (NASDAQ:IRTC), a digital healthcare company specializing in disease detection and prediction solutions, has scheduled its Q2 2025 earnings release for July 31, 2025, after market close.

The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access both the live and archived versions of the webcast through the "Quarterly Results" section on iRhythm's investor relations website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC), a digital healthcare company specializing in disease detection and prevention, announced significant changes to its Board of Directors. Long-serving board members Mark Rubash and Ralph Snyderman, M.D. will retire effective July 7, 2025, after serving since 2016 and 2017 respectively.

The company has appointed Karen McGinnis and Kevin O'Boyle as new board members. Both will serve on the Audit Committee, with O'Boyle also joining the Nominating & Governance Committee. These appointments bring additional financial expertise and operational experience from the medical and biotechnology industry to iRhythm's leadership team.

iRhythm Technologies (IRTC) presented new data at ADA 2025 revealing significant findings about cardiac arrhythmias in type 2 diabetes (T2D) and chronic kidney disease (CKD) patients. The study analyzed over 30 million U.S. adults, showing that of 8.8 million T2D patients, 1.1 million developed major arrhythmias, with 47% occurring post-diabetes diagnosis. In the T2D+CKD population of 3.2 million patients, 21% developed major arrhythmias, with 59% occurring before CKD diagnosis. The research highlighted that arrhythmias often precede major cardiovascular events (MACE), with 17% of patients experiencing MACE within three days of arrhythmia. The findings suggest that early detection of arrhythmias could be crucial for preventing complications, especially since previous data showed that fewer than one in five patients experience symptoms during arrhythmic episodes.

iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection, prevention, and prediction solutions, has announced its management team's participation in three upcoming investor conferences in June 2025:

• William Blair 45th Annual Growth Stock Conference on June 4, 2025, at 2:00 PM CT
• Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 2:40 PM ET
• Truist Securities MedTech Conference on June 17, 2025, at 1:40 PM ET

Live and archived webcasts will be available on the company's investor website at investors.irhythmtech.com.

iRhythm Technologies (NASDAQ:IRTC) has launched its Zio® ECG Recording and Analysis System in Japan, marking its entry into the world's second-largest ambulatory cardiac monitoring market. The system offers up to 14 days of continuous ECG monitoring, powered by PMDA-approved AI algorithms capable of detecting 13 arrhythmia types. The Zio monitor features a lightweight, comfortable patch design with 99% patient compliance and analyzable data rates. The system combines AI technology with human expertise through certified cardiographic technician review, achieving 99% physician agreement. Japan's market, with approximately 1.6 million tests prescribed annually, represents a significant opportunity as the country faces increasing arrhythmia prevalence in its aging population. The nationwide rollout is expected to complete by July 2025, distributed exclusively through Senko Medical Instrument.